多西他赛与表柔比星联合或序贯化疗治疗局部晚期乳腺癌的分析

Analysis of docetaxel combined with epirubicin or sequential chemotherapy in the treatment of locally advanced breast cancer

目的:探讨多西他赛与表柔比星联合或序贯化疗治疗局部晚期乳腺癌的价值。方法:收治晚期乳腺癌患者70例,随机平分为两组,研究组接受表柔比星与多西他赛序贯用药方案,对照组接受表柔比星与多西他赛联合用药方案。对比两组近期疗效、远期疗效及化疗期间不良反应。结果:研究组和对照组局部晚期乳腺癌的治疗疗效分别为92%、74.29%;研究组和对照组1年生存率及1年乳腺癌复发率分别为(85.71%、8.57%)、(60.00%、22.86%);研究组和对照组化疗期间不良反应发生情况及治疗疗效、1年生存率、1年复发率比较,差异均有统计学意义(P<0.05)。结论:多西他赛与表柔比星序贯化疗可以提高局部晚期乳腺癌化疗疗效,减少化疗期间药物不良反应的发生。

Objective:To investigate the value of docetaxel combined with epirubicin or sequential chemotherapy in the treatment of locally advanced breast cancer.Methods:70 patients with locally advanced breast cancer were selecteed,they were randomly divided equally into the two groups,the study group received the sequential medication of epirubicin and docetaxel,and the control group received the combination of epirubicin and docetaxel.The short-term efficacy,long-term efficacy and adverse reactions during chemotherapy were compared between the two groups.Results:The therapeutic effect of the local advanced breast cancer in the study group and the control group was 92% and 74.29%,respectively.The 1 year survival rate and the 1 year recurrence rate of breast cancer in the study group and the control group were(85.71%,8.57%),(60%,22.86%),respectively.There were significant differences in adverse reactions,the differences of the above indicators had statistical significance(P<0.05).Conclusion:Docetaxel and epirubicin sequential chemotherapy can improve the chemotherapy effect of locally advanced breast cancer and reduce the incidence of adverse drug reactions during chemotherapy.